-- 
Netflix, Newcastle, Supervalu, UBS, Zogenix: U.S. Equity Movers

-- B y   N i k o l a j   G a m m e l t o f t
-- 
2011-09-15T20:10:07Z

-- http://www.bloomberg.com/news/2011-09-14/clarcor-pep-boys-transcept-tutor-perini-u-s-equity-preview.html
Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in  New York .  European lenders rallied after the  European Central Bank 
said it will lend dollars to euro-area banks in a series of
three-month loans to ensure they have enough of the U.S.
currency through the end of the year.  BNP Paribas (BNPQY)  SA
surged 15 percent to $21.52.  Deutsche Bank AG (DBK)   jumped 7.7
percent to $35.36.  Credit Suisse Group AG (CSGN)   climbed 7.3
percent to $25.47.  U.S. financial companies gained along with their European
peers.  Morgan Stanley (MS)   added 7.2 percent to $16.59.
 JPMorgan Chase & Co. (JPM)   climbed 3.1 percent to $33.81 and
Bank of America Corp. (BAC US) advanced 4 percent to $7.33.  Aeroflex Holding Corp. (ARX)   gained 9.3 percent, the
most since its initial public offering in November, to $10.01.
The designer of radio frequency and microwave integrated
circuits was added to Goldman Sachs Group Inc.’s conviction buy
list.  Teradyne Inc. (TER) ’s acquisition of LitePoint Corp.
“underscores tremendous value” in Aeroflex, analysts including
James Covello said in a note.  American Superconductor Corp. (AMSC)   fell 15 percent,
the most since June 1, to $6.01. The wind turbine component
maker said it filed a claim for arbitration in  China  against its
largest customer, Sinovel Wind Group Co., seeking payments for
previously refused shipments.  CNinsure Inc. (CISG)   slumped 15 percent to $9.03, the
lowest price since May 2009. The insurance and brokerage company
based in  Guangzhou , China, said a group including Chairman Yinan
Hu withdrew a non-binding proposal to acquire the company.  Fundtech Ltd. (FNDT)   surged 32 percent, a record, to
$23.18. GTCR Fund X/A LP offered to buy the maker of software
for financial institutions for $23.33 per share in cash.  HCA Holdings Inc. (HCA US) rose the most in the Russell
1000 Index, climbing 12 percent to $20.84.  Bank of America Corp. (BAC) 
 agreed to sell 80.8 million shares of the hospital
chain back to the company for $1.5 billion.  Netflix Inc. (NFLX)   dropped 19 percent, the most in the
Standard & Poor’s 500 Index, to $169.30. The mail-order and
online film-rental service cut its forecast for domestic
subscribers in the third quarter. Netflix will have 2.2 million
DVD-only subscribers, down from its previous projection of 3
million. The company also said it will have 9.8 million
streaming-only subscribers, down from 10 million.  Newcastle Investment Corp. (NCT)   jumped 19 percent to
$5.87, the highest level since Aug. 1. The New York-based real
estate investment trust boosted its quarterly dividend to 15
cents a share from 10 cents.  Supervalu Inc. (SVU)   climbed 5.7 percent, the most since
Aug. 29, to $7.92. The supermarket chain was rated “buy” in
new coverage by  Deutsche Bank AG (DB) , which said “credit fears are
overblown” and “sentiment was just too negative relative to
ongoing underlying changes” at the company.  Transcept Pharmaceuticals Inc. (TSPT)   soared 80 percent,
the most in the Russell 2000 Index, to $6.01. The developer of
psychiatry and sleep medicine-related products plans to resubmit
its Intermezzo new drug application for insomnia treatment after
a meeting with the U.S.  Food and Drug Administration .  UBS AG (UBSN)   plunged 10 percent to $11.41, the lowest
price since April 2009.  Switzerland ’s biggest bank said it may
be unprofitable in the third quarter after a $2 billion loss
from unauthorized trading at its investment bank. London police
arrested Kweku Adoboli, a UBS employee, in connection with the
loss, according to a person with knowledge of the matter who
declined to be identified. City of London police and UBS
declined to identify the man.  Zogenix Inc. (ZGNX)   fell 17 percent to $2.17, the lowest
price since its IPO in November. The specialty pharmaceutical
company increased a stock offering to 30 million shares from 12
million, according to a regulatory filing.  To contact the reporter on this story:
Nikolaj Gammeltoft in New York at 
 ngammeltoft@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net  